Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Post-Trial Drug Access
Drugs
Locations
Clinical Specialty
601-620 of 847 trials

Focal Seizures: PRAX-628 Study

We are testing a new medication, PRAX-628, for adults with focal seizures to see if it can reduce seizure frequency compared to a placebo. The study also looks at the safety and tolerability of this treatment.

Focal EpilepsyEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurology

Inclisiran for Children with High Cholesterol

We are studying the safety and effectiveness of inclisiran in children aged 2 to under 12 years with homozygous familial hypercholesterolemia. The goal is to see if it can lower their cholesterol levels compared to a placebo.

Homozygous Familial Hypercholesterolemia>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPediatrics

Progressive Multiple Sclerosis: IMU-838 Study

We are testing a new medication, IMU-838, to see if it helps reduce brain atrophy in patients with progressive multiple sclerosis. This study compares its effects to a placebo to evaluate its safety and tolerability.

Progressive Multiple Sclerosis>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease: CTX001 Treatment

We are studying a new gene therapy using modified stem cells for adolescents and adults with transfusion-dependent β-thalassemia or severe sickle cell disease. The goal is to evaluate its effectiveness and safety in improving their condition.

Transfusion-dependent β-thalassemiaSevere sickle cell disease1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematology

Dazukibart for Idiopathic Inflammatory Myopathies

We are studying the long-term safety and effectiveness of dazukibart in people with dermatomyositis or polymyositis who have completed prior treatment. This research aims to understand how well the medication works in reducing symptoms and improving health.

Idiopathic Inflammatory Myopathy1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesRheumatology

Rett Syndrome: Leriglitazone Study for Children

We are testing the safety and effects of a new medication, leriglitazone, in children with Rett Syndrome. The study aims to understand its impact on development and caregiver challenges.

Rett Syndrome1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyPediatrics

Ulcerative Colitis in Kids: Risankizumab Study

We are evaluating how well Risankizumab works and its safety for children aged 2 to under 18 with moderately to severely active ulcerative colitis. This study will help us understand how the drug is processed in their bodies.

Ulcerative Colitis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyPediatrics

Lung Cancer: Pembrolizumab and Lenvatinib Combination Therapy

We are studying a new combination treatment for patients with operable Non-Small-Cell Lung Cancer to see if it improves response rates before surgery. We also aim to identify markers that may predict how well patients respond to this therapy.

Non-Small-Cell Lung Cancer1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPulmonology

Chronic Lymphocytic Leukemia: Ibrutinib and Obinutuzumab Treatment

We are studying a combination of ibrutinib and obinutuzumab for newly diagnosed patients with Chronic Lymphocytic Leukemia. The aim is to see if this treatment effectively reduces cancer cells in the bone marrow.

Chronic Lymphocytic Leukemia (CLL)>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Advanced Solid Tumors: OSE-279 Treatment Study

We are investigating a new monoclonal antibody, OSE-279, for patients with advanced solid tumors or lymphomas. The study aims to find the best dose and evaluate its safety and effectiveness compared to existing treatments.

Stage IV Non-Small Cell Lung CancerAdvanced Solid TumorsLymphoma1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Vitamin D for Low Testosterone in Men with Type 2 Diabetes

We are studying whether vitamin D supplements can help increase testosterone levels in men with type 2 diabetes. This trial compares the effects of vitamin D to a placebo.

Type 2 Diabetes≤3 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessStandard MedicinesEndocrinologyInternal Medicine

Severe Asthma: Predicting Response to Benralizumab

We are studying whether early blood tests can predict how well severe asthma patients respond to Benralizumab treatment. This may help identify those who are likely to experience fewer asthma attacks.

Severe Asthma>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteAllergologyPulmonology

CRN04894 for Hormonal Imbalance

We are studying the safety and effectiveness of CRN04894 in participants with hormonal imbalances. The goal is to see how it affects hormone levels and overall health.

Congenital Adrenal HyperplasiaEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyPediatrics

MDS and AML: Venetoclax with Azacitidine

We are studying a new treatment combining venetoclax and azacitidine with donor lymphocyte infusion for patients with MDS or AML who have relapsed after a stem cell transplant. The goal is to assess its safety and effectiveness.

Acute Myeloid LeukemiaMyelodysplastic Syndromes>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Hepatocellular Carcinoma: Durvalumab and Tremelimumab Study

We are comparing two treatment methods for patients with liver cancer to see if combining immune therapy with chemotherapy improves outcomes. The study will assess effectiveness, safety, and quality of life.

Hepatocellular Carcinoma (HCC)>2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHepatologyOncology

Lung Cancer: BMS-986507 Treatment Study

We are testing a new treatment called BMS-986507 for adults with advanced lung cancer to see if it is safe and to find the best dose when used with other therapies.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Squamous Cell Carcinoma: Cetuximab with or without Paclitaxel

We are studying the effectiveness of cetuximab alone or with paclitaxel for patients with recurrent head and neck cancer after previous treatment. The goal is to see how these options affect survival and quality of life.

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Peripheral T-Cell Lymphoma: New Drug Evaluation

We are testing new drugs for patients with relapsed or refractory peripheral T-cell lymphomas to see if they are safe and improve treatment outcomes. This trial aims to find better options for those who have not responded to existing therapies.

Relapsed or Refractory Peripheral T-Cell Lymphomas>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Avapritinib: Continued Access for Previous Study Participants

We are offering ongoing access to avapritinib for adults who benefited from it in a prior study. This trial also aims to evaluate the long-term safety of the treatment.

Systemic Mastocytosis6-12 monthsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Thyroid Eye Disease: VRDN-003 Treatment Study

We are investigating whether VRDN-003 can improve symptoms in individuals with active thyroid eye disease. The study will also check if the treatment is safe and well-tolerated compared to a placebo.

Thyroid Eye Disease1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyOphthalmology